ASH Announces 2021 ASH Honorific Award Recipients, Issues New Guidance on Anticoagulation for Discharged Patients With COVID-19, and more

Congratulations to the Recipients of the 2021 ASH Honorific Awards!

The American Society of Hematology (ASH) has announced the recipients of its 2021 Honorific Awards, to be recognized at the 63rd ASH Annual Meeting & Exposition in December.

The Honorific Awards recognize exemplary hematologists who have made significant contributions to the field and have been nominated by ASH members. This year’s recipients are a diverse group of pioneering scientists, innovative clinicians, and selfless mentors who have advanced hematology through a variety of vital contributions, from new insights into red blood cells and the microenvironments of cancers; to improved care for people living with sickle cell disease, anemia, and other blood disorders; to dedicated mentorship of underrepresented minority trainees to bolster a strong, growing, and diverse hematology workforce.

“We commend this year’s Honorific Award recipients, whose achievements highlight what an exciting time it is in our field. Their meaningful advances in patient care, research, and mentorship have directly improved the lives of people living with blood disorders,” said ASH President Martin S. Tallman, MD, of Memorial Sloan Kettering Cancer Center. “The Society continues to value opportunities to recognize talented, inspirational leaders and role models from a broad variety of backgrounds, experiences, and career paths whose contributions are invaluably shaping the future of hematology.”

The 2021 Honorific Awards recipients are:

Wallace H. Coulter Award for Lifetime Achievement in Hematology

  • Harvey Lodish, PhD, Whitehead Institute for Biomedical Research and the Massachusetts Institute of Technology

Ernest Beutler Lecture and Prize

  • Margaret Shipp, MD, Dana Farber/Harvard Cancer Center
  • Stephen Ansell, MD, PhD, Mayo Clinic

Leadership in Promoting Diversity

  • Deepika Darbari, MD, Children’s National Hospital and the George Washington University School of Medicine and Health Sciences

William Dameshek Prize

  • Elizabeta Nemeth, PhD, University of California Los Angeles

E. Donnall Thomas Lecture and Prize

  • Connie Westhoff, PhD, New York Blood Center

Henry M. Stratton Medal

  • Denisa Wagner, PhD, Harvard Medical School and Boston Children’s Hospital
  • Kwaku Ohene-Frempong, MD, Sickle Cell Foundation of Ghana; Director Emeritus, Comprehensive Sickle Cell Center, Children’s Hospital of Philadelphia, Professor Emeritus of Pediatrics, University of Pennsylvania

Mentor Award

  • Jonathan Licht, MD, University of Florida Cancer Center
  • Anthony Goldstone, BM BCh, FRCP, FRCPath, University College London Hospital

Learn more about the ASH Honorific Awards at hematology.org/awards/honorific.


ASH Issues New Guidance on Anticoagulation for Discharged Patients With COVID-19

ASH has released a new recommendation advising against anticoagulation after release from the hospital for most adult patients with COVID-19. The draft recommendation, Recommendation 3, is the latest addition to the ASH Guidelines on Use of Anticoagulation in Patients with COVID-19 and is intended to help hematologists, hospital-based clinicians, and patients as they make decisions about care after hospitalization.

In developing the new recommendation, the guideline panel considered evidence from observational studies suggesting that the benefits of using anticoagulation after discharge did not outweigh the potential harms, including associated bleeding risks and the cost of treatment. The panel also wrote that it remains important for clinicians to evaluate each patient individually, and to consider using post-discharge anticoagulation for patients at high risk for clots and low risk for bleeding.

“The mission of our guideline panel since it was formed has been to continually evaluate emerging data to address questions of anticoagulation – should we be using it, and at what dose – to prevent blood clots,” said Adam Cuker, MD, co-chair of the guideline panel and associate professor of medicine at the University of Pennsylvania. “This recommendation focuses on how we should treat patients who are recovering from COVID-19 and are able to leave the hospital. Early in the pandemic when we were all scrambling to get a handle on this disease, many institutions adopted the practice of routinely using anticoagulation for patients after discharge. But the evidence we have now suggests against using anticoagulation in most instances.”

The new recommendation underwent an open public comment period in July and will be submitted for peer review and publication in Blood Advances. The evidence supporting the recommendation will be maintained through living systematic reviews and updated as needed.

Find this new recommendation and the complete ASH Clinical Practice Guidelines on Venous Thromboembolism at hematology.org/vte.


2021 ASH Annual Meeting Member Registration Now Open!

The 63rd ASH Annual Meeting and Exposition will take place December 11-14, 2021, with an in-person meeting at the Georgia World Congress Center in Atlanta, and as a virtual meeting for those who prefer to participate online.

In-person and virtual registration is now open for ASH members! Non-member and group registration, as well as housing, opens August 11 at 11:00 a.m. Eastern time.

Please note that COVID-19 vaccination will be required of all in-person attendees and advance registration is required for those participating in person.

Find additional information and sign up for email updates at hematology.org/annualmeeting.